IMMUNEONCO-B (01541) Extends Rally, Surges Over 6% After IMM0306S Clinical Trial Approval

Stock News

Mar 09

IMMUNEONCO-B (01541) has risen more than 6%, extending its recent gains. At the time of writing, the stock was up 6.09% to HK$4.70, with a turnover of HK$10.3795 million.

The increase follows the company's announcement that its subsidiary has received approval from China's National Medical Products Administration for the clinical trial application of its new drug, IMM0306S (a subcutaneous formulation), for the treatment of systemic lupus erythematosus (SLE). This landmark development marks a significant breakthrough for IMMUNEONCO-B in the research and development of innovative drugs for autoimmune diseases.

The group holds the global intellectual property rights and commercialization rights for IMM0306S.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1126203337"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1126203337\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1126203337?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-09 13:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126203337","market":"sg","top_or_hot":-1,"title":"IMMUNEONCO-B (01541) Extends Rally, Surges Over 6% After IMM0306S Clinical Trial Approval","media":"Stock News","content":"<p>IMMUNEONCO-B (01541) has risen more than 6%, extending its recent gains. At the time of writing, the stock was up 6.09% to HK$4.70, with a turnover of HK$10.3795 million.</p>\n<p>The increase follows the company's announcement that its subsidiary has received approval from China's National Medical Products Administration for the clinical trial application of its new drug, IMM0306S (a subcutaneous formulation), for the treatment of systemic lupus erythematosus (SLE). This landmark development marks a significant breakthrough for IMMUNEONCO-B in the research and development of innovative drugs for autoimmune diseases.</p>\n<p>The group holds the global intellectual property rights and commercialization rights for IMM0306S.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IMMUNEONCO-B (01541) Extends Rally, Surges Over 6% After IMM0306S Clinical Trial Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIMMUNEONCO-B (01541) Extends Rally, Surges Over 6% After IMM0306S Clinical Trial Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-09 13:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>IMMUNEONCO-B (01541) has risen more than 6%, extending its recent gains. At the time of writing, the stock was up 6.09% to HK$4.70, with a turnover of HK$10.3795 million.</p>\n<p>The increase follows the company's announcement that its subsidiary has received approval from China's National Medical Products Administration for the clinical trial application of its new drug, IMM0306S (a subcutaneous formulation), for the treatment of systemic lupus erythematosus (SLE). This landmark development marks a significant breakthrough for IMMUNEONCO-B in the research and development of innovative drugs for autoimmune diseases.</p>\n<p>The group holds the global intellectual property rights and commercialization rights for IMM0306S.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VXUS","symbol_name":"国际股票ETF-Vanguard","start_time":0,"source_url":"","article_id":"1126203337","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126203337","pubTimestamp":1773035775,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"IMMUNEONCO-B (01541) has risen more than 6%, extending its recent gains. At the time of writing, the stock was up 6.09% to HK$4.70, with a turnover of HK$10.3795 million. The increase follows the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VXUS":"国际股票ETF-Vanguard","01541":"宜明昂科-B","BK4588":"碎股","BK1161":"生物科技","BK4585":"ETF&股票定投概念"},"translate_title":"IMMUNEONCO-B(01541)延续涨势，IMM0306S临床试验获批后飙升逾6%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"01541":1},"content_text":"IMMUNEONCO-B (01541) has risen more than 6%, extending its recent gains. At the time of writing, the stock was up 6.09% to HK$4.70, with a turnover of HK$10.3795 million.\nThe increase follows the company's announcement that its subsidiary has received approval from China's National Medical Products Administration for the clinical trial application of its new drug, IMM0306S (a subcutaneous formulation), for the treatment of systemic lupus erythematosus (SLE). This landmark development marks a significant breakthrough for IMMUNEONCO-B in the research and development of innovative drugs for autoimmune diseases.\nThe group holds the global intellectual property rights and commercialization rights for IMM0306S.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}